Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence

BMC Microbiology

Volumn 11, Issue , 2011, Pages

  Sjögren, Jonathan ^a,b   Okumura, Cheryl Ym ^b,c   Collin, Mattias ^a   Nizet, Victor ^b,c   Hollands, Andrew ^b,d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ENDOGLYCOSIDASE; IMMUNOGLOBULIN HEAVY CHAIN; UNCLASSIFIED DRUG; GLYCOSIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GROUP A STREPTOCOCCAL INFECTION; IN VITRO STUDY; IN VIVO CULTURE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENICITY; PHAGOCYTE; PROTEIN EXPRESSION; SEROTYPE; STREPTOCOCCUS GROUP A; WILD TYPE; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; PATHOLOGY; PHAGOCYTOSIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; VIRULENCE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

ANIMALS; DISEASE MODELS, ANIMAL; GENE DELETION; GLYCOSIDE HYDROLASES; HUMANS; IMMUNOGLOBULIN G; MICE; MICROBIAL VIABILITY; PHAGOCYTES; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VIRULENCE;

EID: 79957456998     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-11-120     Document Type: Article

References (34)

1. Pathogenesis of group A streptococcal infections. MW Cunningham, Clin Microbiol Rev 2000 13 3 470 511 10.1128/CMR.13.3.470-511.2000 10885988 (Pubitemid 30452618)
2. The global burden of group A streptococcal diseases. JR Carapetis AC Steer EK Mulholland M Weber, Lancet Infect Dis 2005 5 11 685 694 10.1016/S1473-3099(05)70267-X 16253886 (Pubitemid 41505357)
3. How group A Streptococcus circumvents host phagocyte defenses. LA Kwinn V Nizet, Future Microbiol 2007 2 75 84 10.2217/17460913.2.1.75 17661677 (Pubitemid 46766999)
4. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. M Collin A Olsén, EMBO J 2001 20 12 3046 3055 10.1093/emboj/20.12.3046 11406581 (Pubitemid 32611992)
5. Biological significance of carbohydrate chains on monoclonal antibodies. M Nose H Wigzell, Proc Natl Acad Sci USA 1983 80 21 6632 6636 10.1073/pnas.80.21.6632 6579549 (Pubitemid 14240149)
6. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. S Krapp Y Mimura R Jefferis R Huber P Sondermann, J Mol Biol 2003 325 5 979 989 10.1016/S0022-2836(02)01250-0 12527303 (Pubitemid 36263407)
7. The impact of glycosylation on the biological function and structure of human immunoglobulins. JN Arnold MR Wormald RB Sim PM Rudd RA Dwek, Annu Rev Immunol 2007 25 21 50 10.1146/annurev.immunol.25.022106.141702 17029568 (Pubitemid 46697901)
8. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. M Collin A Olsén, Infect Immun 2001 69 11 7187 7189 10.1128/IAI.69.11.7187-7189.2001 11598100 (Pubitemid 32995485)
9. Enzymatic deglycosylation of asparagine-linked glycans: purification, properties, and specificity of oligosaccharide-cleaving enzymes from Flavobacterium meningosepticum. AL Tarentino TH Plummer Jr, Methods Enzymol 1994 230 44 57 8139511
10. EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin- mediated opsonophagocytosis. M Collin MD Svensson AG Sjöholm JC Jensenius U Sjöbring A Olsén, Infect Immun 2002 70 12 6646 6651 10.1128/IAI.70.12.6646-6651.2002 12438337 (Pubitemid 35387893)
11. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. M Allhorn AI Olin F Nimmerjahn M Collin, PLoS One 2008 3 1 1413 10.1371/journal.pone.0001413 18183294
12. Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes. M Collin A Olsén, Infection and Immunity 2003 71 6 2983 2992 10.1128/IAI.71.6.2983-2992.2003 12761074 (Pubitemid 36637518)
13. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. JT Buchanan AJ Simpson RK Aziz GY Liu SA Kristian M Kotb J Feramisco V Nizet, Curr Biol 2006 16 4 396 400 10.1016/j.cub.2005.12.039 16488874 (Pubitemid 43259350)
14. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. MA Pence SH Rooijakkers AL Cogen JN Cole A Hollands RL Gallo V Nizet, J Innate Immun 2010
15. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. H Herwald H Cramer M Mörgelin W Russell U Sollenberg A Norrby-Teglund H Flodgaard L Lindbom L Björck, Cell 2004 116 3 367 379 10.1016/S0092-8674(04)00057-1 15016372 (Pubitemid 38366314)
16. Quantitative and qualitative comparison of virulence traits, including murine lethality, among different M types of group A streptococci. T Miyoshi-Akiyama J Zhao K Kikuchi H Kato R Suzuki M Endoh T Uchiyama, J Infect Dis 2003 187 12 1876 1887 10.1086/375348 12792864 (Pubitemid 36724486)
17. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. H Albert M Collin D Dudziak JV Ravetch F Nimmerjahn, Proc Natl Acad Sci USA 2008 105 39 15005 15009 10.1073/pnas.0808248105 18815375
18. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. RK Aziz M Kotb, Emerg Infect Dis 2008 14 10 1511 1517 10.3201/eid1410.071660 18826812
19. Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. P Sumby KD Barbian DJ Gardner AR Whitney DM Welty RD Long JR Bailey MJ Parnell NP Hoe GG Adams,, et al. Proc Natl Acad Sci USA 2005 102 5 1679 1684 10.1073/pnas. 0406641102 15668390 (Pubitemid 40209227)
20. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. MJ Walker A Hollands ML Sanderson-Smith JN Cole JK Kirk A Henningham JD McArthur K Dinkla RK Aziz RG Kansal,, et al. Nat Med 2007 13 8 981 985 10.1038/nm1612 17632528 (Pubitemid 47222039)
21. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. IM Frick P kesson M Rasmussen A Schmidtchen L Björck, J Biol Chem 2003 278 19 16561 16566 10.1074/jbc.M301995200 12621031 (Pubitemid 36799517)
22. Streptococcal M protein: a multipotent and powerful inducer of inflammation. LI Påhlman M Mörgelin J Eckert L Johansson W Russell K Riesbeck O Soehnlein L Lindbom A Norrby-Teglund RR Schumann,, et al. J Immunol 2006 177 2 1221 1228 16818781 (Pubitemid 44036627)
23. Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. P Sumby AR Whitney EA Graviss FR DeLeo JM Musser, PLoS Pathog 2006 2 1 5 10.1371/journal.ppat.0020005 16446783
24. Parameters governing invasive disease propensity of non-M1 serotype group A streptococci. PG Maamary ML Sanderson-Smith RK Aziz A Hollands JN Cole FC McKay JD McArthur JK Kirk AJ Cork RJ Keefe,, et al. J Innate Immun 2010
25. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. M Allhorn JG Briceno L Baudino C Lood ML Olsson S Izui M Collin, Blood 2010 115 24 5080 5088 10.1182/blood-2009-08- 239020 20357243
26. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. KS Nandakumar M Collin A Olsén F Nimmerjahn AM Blom JV Ravetch R Holmdahl, Eur J Immunol 2007 37 10 2973 2982 10.1002/eji.200737581 17899548 (Pubitemid 47578315)
27. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. M Collin O Shannon L Björck, Proc Natl Acad Sci USA 2008 105 11 4265 4270 10.1073/pnas.0711271105 18332429 (Pubitemid 351754369)
28. Sugar-free antibodies - the bacterial solution to autoimmunity? M Allhorn M Collin, Ann N Y Acad Sci 2009 1173 664 669 10.1111/j.1749-6632.2009.04739.x 19758213
29. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. MM van Timmeren BS van der Veen CA Stegeman AH Petersen T Hellmark M Collin P Heeringa, J Am Soc Nephrol 2010 21 7 1103 1114 10.1681/ASN.2009090984 20448018
30. The rgg gene of Streptococcus pyogenes NZ131 positively influences extracellular SPE B production. MS Chaussee D Ajdic JJ Ferretti, Infect Immun 1999 67 4 1715 1722 10085009 (Pubitemid 29144388)
31. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. RG Kansal A McGeer DE Low A Norrby-Teglund M Kotb, Infect Immun 2000 68 11 6362 6369 10.1128/IAI.68.11.6362- 6369.2000 11035746
32. Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. MJ Casadaban SN Cohen, J Mol Biol 1980 138 2 179 207 10.1016/0022- 2836(80)90283-1 6997493 (Pubitemid 10044378)
33. D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. SA Kristian V Datta C Weidenmaier R Kansal I Fedtke A Peschel RL Gallo V Nizet, J Bacteriol 2005 187 19 6719 6725 10.1128/JB.187.19.6719-6725.2005 16166534 (Pubitemid 41356245)
34. A statistically defined endpoint titer determination method for immunoassays. A Frey J Di Canzio D Zurakowski, J Immunol Methods 1998 221 1-2 35 41 10.1016/S0022-1759(98)00170-7 9894896 (Pubitemid 29017921)